Isolation and in vitro characterization of novel S. epidermidis phages for therapeutic applications
- PMID: 37293203
- PMCID: PMC10244729
- DOI: 10.3389/fcimb.2023.1169135
Isolation and in vitro characterization of novel S. epidermidis phages for therapeutic applications
Abstract
S. epidermidis is an important opportunistic pathogen causing chronic prosthetic joint infections associated with biofilm growth. Increased tolerance to antibiotic therapy often requires prolonged treatment or revision surgery. Phage therapy is currently used as compassionate use therapy and continues to be evaluated for its viability as adjunctive therapy to antibiotic treatment or as an alternative treatment for infections caused by S. epidermidis to prevent relapses. In the present study, we report the isolation and in vitro characterization of three novel lytic S. epidermidis phages. Their genome content analysis indicated the absence of antibiotic resistance genes and virulence factors. Detailed investigation of the phage preparation indicated the absence of any prophage-related contamination and demonstrated the importance of selecting appropriate hosts for phage development from the outset. The isolated phages infect a high proportion of clinically relevant S. epidermidis strains and several other coagulase-negative species growing both in planktonic culture and as a biofilm. Clinical strains differing in their biofilm phenotype and antibiotic resistance profile were selected to further identify possible mechanisms behind increased tolerance to isolated phages.
Keywords: Staphylococcus epidemidis; biofilms; phage safety and efficacy; prosthetic joint infections; therapeutic phages.
Copyright © 2023 Štrancar, Marušić, Tušar, Praček, Kolenc, Šuster, Horvat, Janež and Peterka.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
A new bacteriophage infecting Staphylococcus epidermidis with potential for removing biofilms by combination with chimeric lysin CHAPSH3b and vancomycin.mSphere. 2025 Mar 25;10(3):e0101424. doi: 10.1128/msphere.01014-24. Epub 2025 Feb 21. mSphere. 2025. PMID: 39982075 Free PMC article.
-
Staphylococcus epidermidis Phages Transduce Antimicrobial Resistance Plasmids and Mobilize Chromosomal Islands.mSphere. 2021 May 12;6(3):e00223-21. doi: 10.1128/mSphere.00223-21. mSphere. 2021. PMID: 33980677 Free PMC article.
-
Potential of training of anti-Staphylococcus aureus therapeutic phages against Staphylococcus epidermidis multidrug-resistant isolates is restricted by inter- and intra-sequence type specificity.mSystems. 2024 Oct 22;9(10):e0085024. doi: 10.1128/msystems.00850-24. Epub 2024 Sep 9. mSystems. 2024. PMID: 39248470 Free PMC article.
-
Phage susceptibility determinants of the opportunistic pathogen Staphylococcus epidermidis.Curr Opin Microbiol. 2024 Apr;78:102434. doi: 10.1016/j.mib.2024.102434. Epub 2024 Feb 16. Curr Opin Microbiol. 2024. PMID: 38364502 Review.
-
Coagulase-Negative Staphylococci phages panorama: Genomic diversity and in vitro studies for a therapeutic use.Microbiol Res. 2025 Jan;290:127944. doi: 10.1016/j.micres.2024.127944. Epub 2024 Nov 9. Microbiol Res. 2025. PMID: 39550872 Review.
Cited by
-
[Potential of bacteriophage therapy in Germany: evidence and clinical relevance].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Jun;68(6):608-616. doi: 10.1007/s00103-025-04048-y. Epub 2025 Apr 28. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025. PMID: 40293490 Free PMC article. Review. German.
-
Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States.Antibiotics (Basel). 2025 May 29;14(6):553. doi: 10.3390/antibiotics14060553. Antibiotics (Basel). 2025. PMID: 40558145 Free PMC article. Review.
-
Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges.Front Microbiol. 2024 Oct 18;15:1476041. doi: 10.3389/fmicb.2024.1476041. eCollection 2024. Front Microbiol. 2024. PMID: 39493847 Free PMC article. Review.
-
Phage Therapy for Orthopaedic Infections: The First Three Cases from the United Kingdom.Antibiotics (Basel). 2025 Jan 22;14(2):114. doi: 10.3390/antibiotics14020114. Antibiotics (Basel). 2025. PMID: 40001358 Free PMC article.
-
Preparation and pharmacokinetic evaluation of Staphylococcus phage COP-80B for treatment of periprosthetic joint infections in a mouse model.Virus Res. 2025 Jul;357:199592. doi: 10.1016/j.virusres.2025.199592. Epub 2025 May 31. Virus Res. 2025. PMID: 40456366 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases